Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8867361 | 0.91 | MEN1 (0.40) | MEN1KMT2ACYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL9719160 | 0.89 | ALDH1A1 (0.42) | MEN1KMT2ACYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL1408704 | 0.89 | PIN1 (0.42) | MEN1KMT2ACYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL7531627 | 0.85 | MEN1 (0.45) | MEN1KMT2ACYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL3987636 | 0.80 | PKM (0.45) | MEN1KMT2ACYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL888213 | 0.79 | MMP8 (0.55) | MEN1KMT2ACYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL297524 | 0.79 | — | — | |
| SCHEMBL3344606 | 0.79 | ALDH1A1 (0.52) | MEN1KMT2ACYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL675195 | 0.78 | CYP4F2 (0.42) | MEN1KMT2ACYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL721987 | 0.78 | MEN1 (0.46) | MEN1KMT2ACYP4F2CYP4A11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2740738-B1 | PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASE, PREPARATION METHODS AND USES THEREOF | BEIJING FSWELCOME TECH DEVELOPMENT CO LTD (CN) | 2018-03-28 | — | — | EP | disclosed |
| US-9284286-B2 | Specific carboxamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2016-03-15 | — | — | US | disclosed |
| EP-2951156-A1 | SPECIFIC CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2015-12-09 | — | — | EP | disclosed |
| US-9138421-B2 | Platinum compounds for treating cell proliferative diseases, preparation method and use thereof | BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2015-09-22 | — | — | US | disclosed |
| EP-2740738-A1 | PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASE, PREPARATION METHODS AND USES THEREOF | Beijing FSwelcome Technology Development Co., Ltd. (CN) | 2014-06-11 | — | — | EP | disclosed |
| WO-2014082737-A1 | SPECIFIC CARBOXAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2014-06-05 | — | — | WO | disclosed |
| US-20140148468-A1 | SPECIFIC CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2014-05-29 | — | — | US | disclosed |
| US-20140142079-A1 | PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASES, PREPARATION METHOD AND USE THEREOF | BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2014-05-22 | — | — | US | disclosed |
| US-5132475-A | Quaternary ammonium fluoride catalyzed halogenation of carbon acids | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-07-21 | — | — | US | disclosed |
| US-4228300-A | Polycarboxylate ethers | MONSANTO COMPANY (US) | 1980-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142079-A1 | PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASES, PREPARATION METHOD AND USE THEREOF | PCNA, POLI, MKI67 | MEN1 549/4885KMT2A 2526/4885CYP4F2 4163/4885 |
| US-20140148468-A1 | SPECIFIC CARBOXAMIDES AS KCNQ2/3 MODULATORS | KCNQ1, KCNQ2, KCNQ3 | MEN1 2357/4885KMT2A 154/4885CYP4F2 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.